HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating for Prime Medicine (NASDAQ:PRME) and maintained a $10 price target.
October 25, 2024 | 10:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating for Prime Medicine and maintained a $10 price target, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst suggests positive sentiment and potential upside for Prime Medicine's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100